The pediatric glutathione study used age-related growth measurements, not a general adult body-weight endpoint. Those units must remain attached to its results. Primary trial
What was studied
Forty-four children with cystic fibrosis, aged 18 months to ten years, participated in a six-month randomized, double-blind comparison of oral reduced glutathione with placebo. The reported primary measures included weight, BMI, height, and fecal calprotectin. Growth-score changes and calprotectin findings favored glutathione. Measurements were collected repeatedly over follow-up. Primary trial
Our appraisal: percentile points are not percent weight gain
A growth percentile describes a position within a reference distribution. A z score expresses position using a standardized scale. Neither can be relabeled as a percentage increase in kilograms.
For a hypothetical example, moving from the twentieth to the thirtieth percentile is a ten-percentile-point change. It is not a claim that body weight increased by ten percent. Keeping this distinction clear is essential when research uses age- and sex-referenced outcomes.
Several outcomes, separate clinical questions
Growth measurements and a fecal inflammatory marker describe different aspects of the investigation. A marker change should not automatically be interpreted as fewer pulmonary exacerbations, improved lung function, or longer survival. Those outcomes would need their own evidence.
Our full-paper review would inspect baseline nutrition, concurrent treatment, reference standards, missing visits, adherence, and the statistical treatment of repeated observations and multiple primary outcomes. The pediatric population also requires particular care when discussing generalizability: these findings are not a universal supplementation recommendation for children.
Frequently asked questions
Was this an inhaled-glutathione trial?
No. The intervention was oral reduced glutathione.
Does a percentile-point change equal percent body-weight change?
No. They are different scales.
Is a z score a weight in kilograms?
No. It is a standardized position relative to a reference distribution.
Does calprotectin alone establish overall disease control?
No. Its interpretation must remain matched to the measured construct.
Can the findings be assigned to healthy children?
Not without evidence supporting that different population.
Is this a pediatric treatment instruction?
No. Children with cystic fibrosis require care from their clinical team.
What remains before publication?
Complete methods, outcome hierarchy, participant flow, safety reporting, and publication-history checks.